Back to top

Image: Bigstock

Aurinia (AUPH) Catches Eye: Stock Moves up 8.5% in Session

Read MoreHide Full Article

Aurinia Pharmaceuticals Inc. (AUPH - Free Report) was a big mover last session, as its shares rose above 8% on the day. The move came after the company reported fourth-quarter and full-year 2016 earnings. This also led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up almost 142% in the past one-month time frame.

The company has seen one positive estimate revision in the past one-month time frame, while its Zacks Consensus Estimate moved lower over the same period, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Aurinia currently carries a Zacks Rank #4 (Sell).

Aurinia Pharmaceuticals Inc Price

 

Aurinia Pharmaceuticals Inc Price | Aurinia Pharmaceuticals Inc Quote

A better-ranked stock in the Medical - Drugs space is Grifols, S.A. (GRFS - Free Report) sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
    
Is AUPH going up? Or down? Predict to see what others think: Up or Down

More Stock News: 8 Companies Verge on Apple-Like Run       

Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.

A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Grifols, S.A. (GRFS) - free report >>

Aurinia Pharmaceuticals Inc (AUPH) - free report >>